Navigation Links
Groundbreaking Canadian asthma study

A new report published in the prestigious New England Journal of Medicine (NEJM) shows that patients treated with bronchial thermoplasty, the first non-drug treatment for asthma, demonstrated an overall improvement in asthma control.

Co-Principal Investigators, Dr. Gerard Cox, respirologist at St. Joseph’s Healthcare Hamilton’s Firestone Institute for Respiratory Health, and Professor at McMaster University, and Dr. John Miller, Division Head of Thoracic Surgery at St. Joseph’s Healthcare Hamilton and McMaster University authored the study. The study revealed improved asthma control at one year following the bronchial thermoplasty procedure.

The publication entitled, "Asthma Control during the Year after Bronchial Thermoplasty", showed that patients treated with bronchial thermoplasty, compared to another group that did not receive the procedure, showed significant positive changes such as: decreases in asthma attacks, increases in days with no asthma symptoms, improvement in quality of life, reduction in using medication, and an improvement in asthma control.

"These findings are very encouraging and are consistent with earlier trial results on bronchial thermoplasty," explains Dr. Cox. "These results make us hopeful that bronchial thermoplasty may be a new option for asthma patients who have asthma symptoms despite use of current drug therapies."

Bronchial thermoplasty is a minimally invasive procedure that reduces the amount of airway smooth muscle that is responsible for the constriction of airways in asthma patients. Using a flexible bronchoscope through the nose or the mouth, a routine procedure. physicians treat small to medium sized airways with Bronchial Thermoplasty (BT). The BT device generates radio frequency/thermal energy and reduces areas of underlying smooth muscle in the airways. The procedure is completed in three treatment sessions, each lasting less than one hour, and spaced apart by about three weeks. The p rocedure, like many other flexible endoscopy procedures, is done under light anesthesia, and the patient returns home the same day.

The objective of the Asthma Intervention Research (AIR) Trial, led by Drs. Cox and Miller, as part of a global clinical trial, was to examine the effectiveness and safety of bronchial thermoplasty as a treatment for patients with moderate or severe asthma. The randomized controlled trial included 112 patients between the ages of 18-65 at 11 centers in four countries, and followed these patients for one year after treatment.

Several years ago, Dr. John Miller began limited bronchial thermoplasty procedures in patients who were scheduled to have lung surgery. "We saw that this particular way of treating the airway had a profound effect on the smooth muscle and not much else, Dr. Miller explains. "The amount of smooth muscle is significantly reduced by thermoplasty and we recognized that this procedure might therefore be an appropriate treatment for people with asthma."

"I’m quite pleased to say that our experience suggests that the Bronchial Thermoplasty procedure is quite well-tolerated, and it holds considerable promise for patients with asthma."

Asthma is a common disease in which the airways in the lung become inflamed, excess airway mucus is produced, and airways narrow when muscles within the airway walls contract. During an asthmatic attack, in response to an asthma trigger such as an allergen or irritant, the airway smooth muscle may contract leading to airway narrowing and breathing difficulties. Asthma currently affects more than 2 million people in Canada.
'"/>

Source:McMaster University


Related biology news :

1. Canadian youth 4th highest in international obesity study
2. Ocean climate predicts elk population in Canadian Rockies
3. Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows
4. Canadian study shows bilingualism has protective effect in delaying onset of dementia by four years
5. New factor implicated in allergy and asthma attacks
6. Monoclonal antibody reduces exacerbations in asthmatics
7. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
8. Sandia completes depleted uranium study
9. Frog peptides block HIV in lab study
10. Experimental shingles vaccine proves effective in nationwide study
11. Patient-choice C-section rate rises 36%: HealthGrades study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... 7, 2016 BioCatch , the global leader ... patent portfolio, which grew to over 40 granted and pending patents. ... , , ... entitled " System, Device, and Method Estimating Force Applied to ... makers to forego costly hardware components needed to estimate the force and ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 Eurofins announces the appointment of Sean Murray ... Scientific Inc. (ESI). Mr. Murray will bring valuable ... entrepreneurial experience in leading international business teams. As the National Division ... to uphold Eurofins, status as the global leader in bio-analytical testing ... , , ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), The Molecular ... with the launch of the SureSeq myPanel™ NGS Custom FH ... familial hypercholesterolemia (FH). The panel delivers single nucleotide variation (SNV) ... panel and allows customisation by ,mix and match, of fully-optimised ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, ... is one of just six company finalists in the Health & Medicine category. ... companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
Breaking Biology Technology: